The emergence of bacteria that co-express serine-and metallo-carbapenemases is a threat to the efficacy of the available β-lactam antibiotic armamentarium. The 4-amino-1,2,4-triazole-3-thione scaffold has been selected as the starting chemical moiety in the design of a small library of β-Lactamase inhibitors (BLIs) with extended activity profiles. The synthesised compounds have been validated in vitro against class A serine β−Lactamase (SBLs) KPC-2 and class B1 metallo β−Lactamases (MBLs) VIM-1 and IMP-1. Of the synthesised derivatives, four compounds showed cross-class micromolar inhibition potency and therefore underwent in silico analyses to elucidate their binding mode within the catalytic pockets of serine-and metallo-BLs. Moreover, several members of the synthesised library have been evaluated, in combination with meropenem (MEM), against clinical strains that overexpress BLs for their ability to synergise carbapenems.

4-amino-1,2,4-triazole-3-thione as a promising scaffold for the inhibition of serine and metallo-β-lactamases

Gianquinto E.;Spyrakis F.;
2020

Abstract

The emergence of bacteria that co-express serine-and metallo-carbapenemases is a threat to the efficacy of the available β-lactam antibiotic armamentarium. The 4-amino-1,2,4-triazole-3-thione scaffold has been selected as the starting chemical moiety in the design of a small library of β-Lactamase inhibitors (BLIs) with extended activity profiles. The synthesised compounds have been validated in vitro against class A serine β−Lactamase (SBLs) KPC-2 and class B1 metallo β−Lactamases (MBLs) VIM-1 and IMP-1. Of the synthesised derivatives, four compounds showed cross-class micromolar inhibition potency and therefore underwent in silico analyses to elucidate their binding mode within the catalytic pockets of serine-and metallo-BLs. Moreover, several members of the synthesised library have been evaluated, in combination with meropenem (MEM), against clinical strains that overexpress BLs for their ability to synergise carbapenems.
PHARMACEUTICALS
13
3
52
67
4-amino-1,2,4-triazole-3-thione; Bacterial resistance; Broad-spectrum activity; Non-covalent inhibition; Structure-based drug design; Thione/thiol tautomerism
Linciano P.; Gianquinto E.; Montanari M.; Maso L.; Bellio P.; Cebrian-Sastre E.; Celenza G.; Blazquez J.; Cendron L.; Spyrakis F.; Tondi D.
File in questo prodotto:
File Dimensione Formato  
pharmaceuticals-13-00052.pdf

accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.88 MB
Formato Adobe PDF
1.88 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1737501
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact